Cauvin C, Tejerina M, van Breemen C
Department of Pharmacology, University of Miami School of Medicine, Florida 33101.
Am J Physiol. 1987 Dec;253(6 Pt 2):H1612-7. doi: 10.1152/ajpheart.1987.253.6.H1612.
The effects of atriopeptin III (AP III) were determined on agonist-induced [i.e., 10(-4) M norepinephrine (NE)] and depolarization-induced (80 mM K+) contractions of isolated mesenteric resistance vessels (ID approximately 100 microns) from spontaneously hypertensive rats (SHR) and from normotensive control Wistar-Kyoto (WKY) rats. The vessels from both groups, when activated by 80 mM K+, were unaffected by AP III. However, activation of WKY vessels by 10(-4) M NE (both phasic and tonic contraction) was inhibited quite effectively and potently by AP III, whereas that in SHR vessels was much less inhibited. In the WKY rat vessels, the concentration of AP III that inhibited contraction by 50% for NE-induced phasic tension was 3.1 +/- 1.3 nM, whereas in SHR vessels it was nearly 1 microM. Comparison of AP III inhibition of NE-induced phasic tension to that at 5 min of activation (tonic tension) indicated that the tonic contractions were less sensitive to AP III than the phasic contractions in the vessels from both strains. A similar experiment indicated that AP III was a potent inhibitor of agonist-induced activation in a human renal resistance vessel (ID 125 microns) and that this vessel depended virtually completely on extracellular Ca2+ for NE-induced contraction. These studies contrast with earlier reports (1, 30) that similar peptides inhibited tension only in rat renal resistance vessels and not in resistance vessels from other vascular beds. The decreased sensitivity and efficacy of AP III in inhibiting tension in SHR compared with WKY mesenteric resistance vessels is discussed in the context of the etiology of spontaneous hypertension.
研究了心房肽III(AP III)对来自自发性高血压大鼠(SHR)和正常血压对照Wistar-Kyoto(WKY)大鼠的离体肠系膜阻力血管(内径约100微米)的激动剂诱导的[即10⁻⁴M去甲肾上腺素(NE)]和去极化诱导的(80 mM K⁺)收缩的影响。两组的血管在被80 mM K⁺激活时,不受AP III的影响。然而,10⁻⁴M NE激活WKY血管(包括相性和张力性收缩)时,AP III能非常有效且有力地抑制,而SHR血管中的抑制作用则小得多。在WKY大鼠血管中,使NE诱导的相性张力收缩抑制50%的AP III浓度为3.1±1.3 nM,而在SHR血管中则接近1 μM。比较AP III对NE诱导的相性张力的抑制与激活5分钟时的抑制(张力性收缩)表明,在两种品系的血管中,张力性收缩对AP III的敏感性低于相性收缩。一项类似的实验表明,AP III是人类肾阻力血管(内径125微米)中激动剂诱导激活的有效抑制剂,并且该血管几乎完全依赖细胞外Ca²⁺进行NE诱导的收缩。这些研究与早期报告(1, 30)形成对比,早期报告称类似肽仅抑制大鼠肾阻力血管的张力,而不抑制其他血管床阻力血管的张力。在自发性高血压的病因背景下,讨论了与WKY肠系膜阻力血管相比,AP III在抑制SHR张力方面敏感性和效力降低的情况。